Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
1.145
-0.025 (-2.14%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Can-Fite BioPharma Revenue
In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K, down -9.29%. Can-Fite BioPharma had revenue of $179.00K in the quarter ending December 31, 2024, with 15.48% growth.
Revenue (ttm)
$674.00K
Revenue Growth
-9.29%
P/S Ratio
25.51
Revenue / Employee
$134,800
Employees
5
Market Cap
17.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
CANF News
- 10 days ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire
- 12 days ago - Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 5 weeks ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire
- 5 weeks ago - Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - GlobeNewsWire
- 7 weeks ago - Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewsWire
- 2 months ago - Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25 - GlobeNewsWire
- 2 months ago - Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 - GlobeNewsWire
- 4 months ago - Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson - GlobeNewsWire